… platinum-based therapy and gefitinib became ineffective conceptually. Thus, the PFS2 in
the gefitinib group was the period from randomization to PD of the second-line therapy or death…

… Two thousand nine, the year the Iressa Pan-Asia Study (IPASS) results were published,
marked a watershed year for targeted therapy in non–small-cell lung cancer (NSCLC). Before …

… Lung cancer is the most commonly occurring cancer worldwide and nearly 80-85 per … lung
cancer (NSCLC) 1 . Globocan estimate of lung cancer indicated that incidence of lung cancer …

… with gefitinib were included for analysis. 1,377 circRNAs were differentially expressed in
gefitinib … by RT-qPCR in an independent cohort of 38 gefitinib-treated NSCLC patients. Elevated …

… , gefitinib therapy is associated with a range of adverse reactions including rash, diarrhea,
lung … Therefore, it demands an urgent need to develop a suitable gefitinib delivery system to …

… of gefitinib in combination with pemetrexed-carboplatin versus gefitinib monotherapy in …
Another Phase III study showed the addition of pemetrexed-carboplatin to gefitinib therapy …

… , gefitinib, cetuximab, or trastuzumab), or other lung cancer chemotherapy or systematic
antitumor therapy, and patients with EGFR-T790M mutations were ineligible for this study. …

… The WJOG 5108L study was a randomized phase III study comparing gefitinib … gefitinib in
terms of PFS compared with erlotinib [7]. The LUX-Lung 7 trial compared afatinib with gefitinib …

… whether the it gefitinib targets the lung cancer cells. Moreover, the so-called … lung tissues
may be invaded by the adjacent lung cancer cells. The high lung tissue distribution of gefitinib is …

… gefitinib-resistant mutation EGFR T790M, as is gefitinib against the osimertinib-resistant EGFR
C797S. Preclinical evidence suggests dual EGFR inhibition with gefitinib … prior therapy for …